NYSE$BHC

Bausch Health Companies Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Bausch Health announced second-quarter 2023 results, raised full-year 2023 revenue outlook, and provided other key updates from the quarter.

Bausch Health reported a strong second quarter with revenue of $2.17 billion, up 10% reported and 11% organic. GAAP net income attributable to Bausch Health Companies Inc. was $26 million, and adjusted EBITDA was $727 million, up 4%. The company raised its full-year revenue outlook and reaffirmed its adjusted EBITDA guidance.

  • Favorable Motion Ruling in Xifaxan® Litigation Reinforces Continuing Salix Growth Strategy
  • Balance Sheet Initiatives Further Enhance Liquidity Profile
  • Continued Evaluation of Optimal Implementation of Potential Bausch + Lomb Distribution
  • Revenue of $2.17 billion, Up 10% Reported and 11% Organic

Headline financials

Total Revenue

$2.17B

Previous: $1.97B+10.2%
EPS (adj)

$0.81

Previous: $0.55+47.3%
Adjusted EBITDA

$727M

Previous: $701M+3.7%
Capital Expenditures

-$75M

Previous: -$98M+23.5%
Free Cash Flow

-$49M

Previous: -$243M+79.8%
Net Income

$26M

Previous: -$145M+117.9%
Operating Income

$412M

Previous: $161M+155.9%
Gross Profit

$1.52B

Previous: $1.39B+9.2%
Cash & Equivalents

$579M

Previous: $659M-12.1%
Total Assets

$25.5B

Previous: $28.2B-9.5%
Stock-Based Comp

$33M

Previous: $26M+26.9%

Revenue & EPS history

Bausch Health · Revenue · Quarterly

$2.17B

Q2 2023+10.2%vs Q2 2022
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Bausch Health · $1.82B total across 3 segments · Q2 2023

  • Bausch + Lomb/International
    $1.04B+10.0%
  • Salix
    $557M+11.2%
  • Diversified Products
    $228M-3.0%

Forward guidance

The Company increased its full year revenue guidance and reaffirmed its Adjusted EBITDA1 guidance for Total Bausch Health

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+0.2%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-1.9%

Avg return

30 days after

51%

35 / 68 earnings

Positive

+30.6%

Q1 2017

Best reaction

-21.5%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+10.9%+0.9%-4.1%
Q4 2025-4.5%-2.7%-19.1%
Q3 2025+12.4%+14.2%+7.6%
Q1 2025+0.0%-10.6%-14.5%
Q4 2024+10.3%+15.8%+10.0%
Q3 2024+12.7%+13.5%+2.6%
Q2 2024-6.6%-10.6%-1.7%
Q1 2024-10.6%-15.3%-25.0%
Q4 2023+5.9%+5.9%+10.3%
Q3 2023+6.9%+2.4%+4.0%
Q2 2023-2.9%-4.6%-9.3%
Q1 2023-21.2%-20.8%+11.2%
Q4 2022+10.8%+7.8%-16.3%
Q3 2022+7.5%+8.4%+21.4%
Q2 2022-3.3%+2.9%+14.7%
Q1 2022-21.5%-16.0%-35.0%
Q4 2021-1.9%+1.9%-3.3%
Q3 2021-4.5%-1.9%-17.8%
Q2 2021-15.5%-10.1%-0.7%
Q1 2021-10.8%-10.6%+0.9%
Q4 2020-0.9%+0.6%-1.8%
Q3 2020-3.1%-4.0%+11.0%
Q2 2020-7.2%-9.2%-16.3%
Q1 2020-1.8%+0.2%+12.4%
Q4 2019-5.8%-7.3%-51.3%
Q3 2019+0.8%+1.1%+10.6%
Q2 2019-4.0%-3.0%-6.9%
Q1 2019+8.7%+8.0%-9.0%
Q4 2018-6.7%-7.3%-2.0%
Q3 2018+6.1%+6.4%-5.2%
Q2 2018+5.4%-2.9%-7.3%
Q1 2018+11.5%+14.8%+37.4%
Q4 2017-17.5%-16.8%-13.9%
Q3 2017+23.6%+27.7%+46.4%
Q2 2017-8.5%-9.6%-12.9%
Q1 2017+30.6%+40.0%+36.6%
Q4 2016-18.7%-21.8%-33.7%
Q3 2016-15.9%-5.9%-19.3%
Q2 2016+21.7%+11.0%+33.5%
Q1 2016-17.1%-16.3%-18.6%
Q4 2015-7.4%
Q3 2015-17.4%
Q2 2015+5.4%
Q1 2015+5.6%
Q4 2014+14.7%
Q3 2014+8.5%
Q2 2014-6.1%
Q1 2014-1.6%
Q4 2013-1.0%
Q3 2013+2.0%
Q2 2013+6.2%
Q1 2013+1.8%
Q4 2012+1.3%
Q3 2012-2.6%
Q2 2012+2.2%
Q1 2012+2.1%
Q4 2008+6.3%
Q4 2010+6.3%
Q4 2011+6.3%
Q3 2011-2.9%
Q2 2011+3.9%
Q1 2010+0.0%
Q1 2011+6.3%
Q3 2010-5.4%
Q3 2009-5.4%
Q2 2009+2.0%
Q2 2010+2.0%
Q4 2009+2.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro